Indication
Surufatinib
1 clinical trial
3 drugs
Clinical trial
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract CancerStatus: Not yet recruiting, Estimated PCD: 2024-06-01
Drug
AdebrelimabDrug
TiragolumabDrug
PD-1 antibody